Back to all bills
HR 1117119th CongressIntroduced
Responsibility in Drug Advertising Act of 2025
Introduced: Oct 29, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs
The House version of the Responsibility in Drug Advertising Act restricts direct-to-consumer drug advertising for the first 3 years after FDA approval.
Key Points
- 1Prohibits direct-to-consumer drug advertising for first 3 years after FDA approval
- 2Allows FDA waiver in third year if determined to have public health value
- 3Authorizes FDA to prohibit advertising later if significant adverse effects are found
- 4Applies to all forms of advertising including social media
- 5Requires FDA to revise advertising regulations within 1 year
- 6Applies only to drugs approved on or after 1 year before enactment
Impact Areas
Pharmaceutical industry marketing practicesDirect-to-consumer drug advertisingFDA regulation and drug safetyConsumer health and medication decisions
Generated by kwaipilot/kat-coder-pro:free on Nov 19, 2025